Quantum Leap Healthcare Collaborative
search

I-SPY in the News

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

MammaPrint and BluePrint's use in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients

Media Contact:

Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org